MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/jpr3.70190

Медицинская библиотека · JPGN reports · 2026

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease.

Mahajan Smridhi, Wysocki Christian, Gurram Bhaskar

СтатьяПеревод в очереди

Аннотация

Infantile-onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very-early-onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited. We conducted a retrospective chart review of four patients treated with tofacitinib in combination with ustekinumab after failing multiple agents at a tertiary referral center. All four patients demonstrated clinical, laboratory, and endoscopic remission. No adverse events were observed. Genetic evaluation did not reveal monogenic causes in any of these patients. These findings suggest that JAKI may represent a safe and effective therapeutic option for carefully selected patients with difficult-to-treat IOIBD, either as a bridge to or in combination with ustekinumab. Larger prospective studies are warranted to better define the role of JAKI in this challenging patient population.

Для цитирования: Mahajan Smridhi, Wysocki Christian, Gurram Bhaskar. The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease.. JPGN reports. 2026. DOI: 10.1002/jpr3.70190.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.